(Press-News.org)
The integration of oncolytic viruses (OVs) with immunotherapy is reshaping the landscape of tumor treatment, offering new hope for patients. This cutting-edge approach harnesses the ability of OVs to selectively infect and destroy tumor cells, while simultaneously stimulating anti-tumor immune responses. The latest advancements in genetic engineering have further optimized these therapies, leading to improved clinical outcomes and enhanced patient quality of life.
By combining OVs with cellular immunotherapy, immune checkpoint inhibitors, cancer vaccines, cytokines, and bi- or tri-specific T cell engagers, researchers have developed innovative strategies that overcome the limitations of OV monotherapy. These synergistic treatments amplify the body’s natural defenses, creating a powerful dual attack against cancer cells while minimizing adverse effects.
One of the key breakthroughs in this field has been the ability to genetically modify OVs to enhance their tumor-targeting efficiency. Modified viruses can express immune-stimulating molecules, improving their ability to recruit and activate immune cells within the tumor microenvironment. This has led to remarkable improvements in tumor eradication, particularly in difficult-to-treat cancers.
The potential of OV-based combination therapies extends across multiple cancer types, including solid tumors, where conventional treatments often fall short. With ongoing clinical trials and continued research into the underlying anti-tumor mechanisms, these therapies are expected to become a cornerstone of next-generation cancer treatment.
As the field of precision medicine continues to evolve, oncolytic virus-based combination immunotherapy is emerging as a promising and effective strategy for patients worldwide. With its ability to enhance immune activation, improve treatment efficacy, and reduce toxicity, this novel approach represents a significant step forward in the fight against cancer.
# # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
Scopus CiteScore: 8.4
Impact Factor: 9.4
# # # # # #
More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases ).
Submissions to Genes & Disease may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx ).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.com
X (formerly Twitter): @GenesNDiseases (https://x.com/GenesNDiseases )
# # # # # #
Reference
Xiaoli Zhou, Shunfeng Hu, Xin Wang, Recent advances in oncolytic virus combined immunotherapy in tumor treatment, Genes & Diseases, Volume 12, Issue 6, 2025, 101599, https://doi.org/10.1016/j.gendis.2025.101599
Funding Information:
National Natural Science Foundation of China 82270200
National Natural Science Foundation of China 82070203
National Natural Science Foundation of China 81770210
National Natural Science Foundation of China 82400231
Taishan Scholars Program of Shandong Province, China; Shandong Provincial Engineering Research Center of Lymphoma (China); Key Research and Development Program of Shandong Province, China (No. 2018CXGC1213)
Academic Promotion Programme of Shandong First Medical University (China) 2019QL018
Translational Research Grant of the National Clinical Research Center for Hematologic Diseases (NCRCH) (China) 2021WWB02
Translational Research Grant of the National Clinical Research Center for Hematologic Diseases (NCRCH) (China) 2020ZKMB01
China Postdoctoral Science Foundation 2023M741506
Shandong Provincial Natural Science Foundation (China) ZR2023QH193
END
Head and neck cancer remains a major global health challenge, ranking among the six most common cancers worldwide and claiming hundreds of thousands of lives each year. A growing body of evidence now points to an intricate connection between energy metabolism and immune regulation as a driving force behind the onset, progression, and treatment resistance of these cancers. The latest comprehensive review on this topic underscores the potential of targeting these intertwined processes to unlock more effective therapies.
Tumor cells in head and neck cancer exhibit profound metabolic reprogramming, altering the way they process glucose, lipids, and ...
BATON ROUGE – Pennington Biomedical Research Center is proud to announce that Dr. Steven B. Heymsfield, Professor of Metabolism and Body Composition, has been named a Boyd Professor of Louisiana State University – the highest faculty rank and honor awarded within the LSU System.
The Boyd Professorship is reserved for faculty whose outstanding achievements and international reputations bring significant prestige to LSU. Dr. Heymsfield joins an elite group of scholars recognized for advancing knowledge and transforming ...
Hed: Study prompts new theory of human-machine communication
LAWRENCE – In a new paper, two University of Kansas scholars propose a novel theory of communication analysis that takes into better account how people interact with ubiquitous technology in the 21st-century workplace.
In “Socio-Technical Exchange with Machines: Worker Experiences with Complex Work Technologies,” ----- link to https://doi.org/10.30658/hmc.10.3 ----------- in the Human-Machine Communications ...
UNIVERSITY PARK, Pa. — Essentially all cells in an organism’s body have the same genetic blueprint, or genome, but the set of genes that are actively expressed at any given time in a cell determines what type of cell it will be and its function. How rapidly gene expression in a single cell changes over time can provide insight into how cells might become more specialized, but current measurement approaches are limited. A new method developed by researchers at Penn State and Yale University incorporates spatial information from the cell as well as data from cells processed at different times, improving researchers’ ability to understand the nuances of gene expression ...
The movement of genetic material between organisms that aren’t directly related is a significant driver of evolution, especially among single-celled organisms like bacteria and archaea. A team led by researchers at Bigelow Laboratory for Ocean Sciences have now estimated that an average cell line acquires and retains roughly 13 percent of its genes every million years via this process of lateral gene transfer. That equates to about 250 genes swapped per liter of seawater every day.
The new study, recently published in The ISME Journal, provides the first quantitative analysis of gene transfer rates across an entire microbiome. It calls into question the strict classification ...
The U.S. Air Force awarded startup SkyNano, led by Innovation Crossroads alumna Anna Douglas, a $1.25 million contract to advance its CO2-to-carbon nanotube technology as part of a project to develop low-cost, battery-grade graphite. SkyNano’s partners include American Energy Technologies Company and Eonix, led by Innovation Crossroads alumnus Don DeRosa.
SkyNano and Eonix were recruited to Knoxville through Innovation Crossroads, a Lab-Embedded Entrepreneurship Program node at Oak Ridge National Laboratory.
“In addition to accessing ...
Some of the populations with the highest risk for Alzheimer’s disease remain greatly underrepresented in clinical trials—and a new study helps explain why. Researchers from the Keck School of Medicine of USC found that participants from these high-risk groups are less likely to have elevated amyloid in the brain based on blood levels of p-tau217. Elevated amyloid is a requirement for clinical trials of Alzheimer’s disease treatments, and amyloid is known to accumulate in the brain years before any signs of cognitive decline.
The study, funded in part by the National Institutes of Health (NIH), builds on earlier research with similar findings, but leverages ...
This review article highlights the transformative potential of in vivo CAR T cell therapy in addressing the limitations of traditional CAR T cell production. This innovative approach could revolutionize cancer treatment, offering a more efficient, scalable, and cost-effective alternative to conventional methods.
CAR T cell therapy has shown remarkable success in treating hematological malignancies; however, current production methods are laborious, time-consuming, and expensive. Traditional in vitro CAR T cell production typically requires 2–3 weeks and involves complex processes, including T cell isolation, activation, genetic modification, ...
Recent advances in cancer treatment highlight the potential of natural medicines to target the tumor vascular microenvironment, offering a novel strategy to inhibit tumor growth and metastasis. Unlike conventional therapies that directly target tumor cells, natural compounds focus on normalizing tumor vasculature and inhibiting pathological angiogenesis, crucial processes in cancer progression. This innovative approach holds promise in enhancing anti-cancer therapies while minimizing side effects.
The tumor vascular microenvironment plays a pivotal role in cancer development. Tumor blood vessels are often irregular, immature, ...
In the depths of the ocean, marine corals have evolved intricate, porous structures that shelter diverse microbial communities.
Now, researchers have borrowed this biological blueprint to create an ingestible pill that can sample bacteria from one of the most inaccessible regions of the human body: the small intestine.
The CORAL (Cellularly Organized Repeating Lattice) capsule, developed by Khalil Ramadi – assistant professor of bioengineering at NYU Tandon School of Engineering and NYU Abu Dhabi (NYUAD) – and ...
